https://www.marketwatch.com/story/cassa ... 2020-09-14
Interesting.....
Cassava Phase II Results
Re: Cassava Phase II Results
Interesting to see how it does with a larger trial. This one was with 64 patients.
Here's a little bit on how it works: https://www.cassavasciences.com/pti-125
There is more info on the markers they reported at https://www.cassavasciences.com/news-re ... ical-studyIn addition, Alzheimer’s patients treated with sumifilam showed directional improvements in tests of remembering new information, versus patients on placebo. Improvements in cognition correlated most strongly with decreases in P-tau181, a biomarker that, when elevated, leads to tangles in the brain. Sumifilam decreased brain levels of Ptau-181 by 8-11%, versus placebo.
In this study, Alzheimer’s patients treated with 50 mg or 100 mg of sumifilam twice-daily for 28 days showed statistically significant (p<0.05) improvements in biomarkers of disease pathology, neurodegeneration and neuroinflammation, versus Alzheimer’s patients who took placebo. In addition, Alzheimer’s patients treated with sumifilam showed directional improvements in validated tests of episodic memory and spatial working memory, versus patients on placebo (Effect Sizes 46-17%). Cognitive improvements correlated most strongly (R2=0.5) with decreases in P-tau181. The study achieved a 98% response rate, defined as the proportion of study participants taking sumifilam who showed improvements in biomarkers.
Here's a little bit on how it works: https://www.cassavasciences.com/pti-125
-
- Contributor
- Posts: 168
- Joined: Wed Jan 06, 2016 8:46 pm
Re: Cassava Phase II Results
SusanJ, the biomarker details are pretty interesting. I find it very interesting that they were able to achieve these results in only 28 days.
However, I'm more hopeful for ALZ 801 https://www.biospace.com/article/releas ... s-disease/.
However, I'm more hopeful for ALZ 801 https://www.biospace.com/article/releas ... s-disease/.